Devyser and QIAGEN collaborate on pre-analytical workflow for fetal RHD screening
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
News | May 4, 2016
Devyser Holding AB announced at its annual general meeting yesterday the appointment of two new board members, Ernst Westman and Lars Höckenström.
Ernst Westman is CEO of the boule diagnostics group since 22 years. Lars Höckenström is currently a senior adviser at Stockholm corporate finance. Chairman of the board Mia Arnhult comments:
"I am delighted to have Ernst Westman and Lars Höckenström on Devyser’s board. Their combined experience and expertise within both the diagnostics industry and finance will greatly benefit our work.
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
Read More
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
Read More
“The first quarter of the year saw continued strong growth, record gross margin and the launching...
Read More
Devyser is today announcing that the company’s clinical testing laboratory in Roswell in Atlanta,...
Read More